Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-02-02
2009-02-10
Szperka, Michael (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S133100, C424S134100, C424S144100, C424S185100, C424S192100, C530S388220, C530S866000, C530S868000
Reexamination Certificate
active
07488804
ABSTRACT:
The present invention comprises a fusion molecule comprising a Fcε fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CHε2-CHε3-CHε4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgG1heavy chain (γhinge-CHγ2-CHγ3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.
REFERENCES:
patent: 3187748 (1965-06-01), Mitchell et al.
patent: 3656070 (1972-04-01), Monaghan et al.
patent: 3658059 (1972-04-01), Steil
patent: 3814297 (1974-06-01), Warren
patent: 3826413 (1974-07-01), Warren
patent: 4208479 (1980-06-01), Zuk et al.
patent: 4527769 (1985-07-01), Stogner et al.
patent: 4592348 (1986-06-01), Waters, IV et al.
patent: 4648393 (1987-03-01), Landis et al.
patent: 4677975 (1987-07-01), Edgar et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4790305 (1988-12-01), Zoltan et al.
patent: 4803978 (1989-02-01), Johnson et al.
patent: 4896832 (1990-01-01), Howlett
patent: 4922901 (1990-05-01), Brooks et al.
patent: 4926852 (1990-05-01), Zoltan et al.
patent: 4943529 (1990-07-01), Van Den Berg et al.
patent: 5329028 (1994-07-01), Ashkenazi et al.
patent: 2003/0082190 (2003-05-01), Saxon et al.
patent: 2004/0198961 (2004-10-01), An et al.
patent: WO 98/09344 (1988-03-01), None
patent: WO 92/09300 (1991-11-01), None
patent: WO 02/088317 (2002-11-01), None
patent: WO 02/102320 (2002-12-01), None
patent: WO 02102320 (2002-12-01), None
Zhu et al., Nature Medicine, 2002, 8:518-521.
Adamczewski, M., Chemical Immun., 59:173-190 1994.
Adelman et al.,DNA2:183 1983.
Altschul et al., “Gapped BLAST and PSI-BLAST: A New generation of protein database search programs”, 25:3389-3402, (1997).
Ashman et al., J. Immunol, 157:5-11 1996.
Ballance et al., Biochem. Biophys. Res. Commun., 112:284-289 1983.
Barnes, The New England Journal of Medicine, 341:2006-2008 1999.
Beach and Nurse, Nature 290:140 1981.
Beasley et al., J. Allergy Clin. Immunol., 105:466-472 2000.
Benoist and Mathis, Arthritis Res. vol. 2:90-94 2000.
Blom et al., Eur J Immunol., 22, 2025-32 1992.
Blom et al., Scand J Immunol., 44, 54-61 1996.
Blondel et al, Protein Engineering, 4:457-461 1991.
Botstein et al., Science 229:1193 1985.
Brake et al., Proc. Natl. Acad. Sci., 81:4642-4646 1984.
Cambier et al, Proc. Natl. Acad. Sci. 94:5993-5995 1997.
Carter et al., Nucl. Acids Res., 13:4331 1986.
Chan et al., Immunology, 21:967-981 1971.
Daeron et al., Immunity, 3:635-646 1995.
Daeron et al., J. Clin. Invest., 95:577-85 1995.
Daeron et al, Annu. Rev. Immunol., 5:203-234 1997.
Delespesse et al., Immunol. Rev. 125:77-97 1992.
Dombrowicz et al., Journal of Immunology 157, 1645-1651. 1996.
Ellison et al., DNA 1:11-18 1982.
Ellison et al., Nucl. Acid Res. 10:4071-4079 1982.
Ellison et al., Proc. Nat. Acad. Sci. 79:1984-1988 1982.
Fiebiger et al., J. Clin. Invest. 96:2606-12 1995.
Fiebiger et al., J. Clin. Invest. 101:243-251, (1998).
Fridman, W., FASEB J, 5(12):2684-90 1991.
G. Barany and R. B. Merrifield, The Peptide: Analysis Synthesis, Biology, editors E. Gross and J. Meienhofer, vol. 2, Academic Press, New York, (1980), pp. 3-254.
Gollnick et al., J. Immunol. 144:1974-82 1990.
Graham et al, J. Gen. Virol. 36:59 1977.
Hellman, Eur. J. Immunol. 23:159-167 1992.
Helm et al., J. Cell Biol. 271(13):7494-7500 1996.
Hide et al., N. Engl. J. Med. 328:1599-1604 1993.
Ji, T.H. “Bifunctional Reagents”, Meth. Enzymol. 91:580-609, (1983).
Kaplan, A. P., Urticaria and Angioedema, In:Inflammation: Basic Principles and Clinical Correlates(Galliin and Snyderman eds.), 3rd Edition, Lippincott & Wilkins, Philadelphia, 1999, pp. 915-928.
Kelly and Hynes, EMBO J. 4:475-479 1985.
Kikutani et al., Cell 47:657-665 1986.
Kinet, J. P., Annu. Rev. Immunol., 17:931-972 1999.
Kondo et al., Int. Arch. Allergy Immunol., 105:38-48 1994.
Krawinkel et al., EMBO J. 1:403-407 1982.
Kunkel et al., Methods Enzymol. 154:367-82 1987.
Landschulz, W. H., et al. Science 240:1759-1764 1988.
Ludin et al.,EMBO J.6:109-114 1987.
Ma et al., J Allergy Clin. Immunol., 112:784-8 2003.
Malbec and Fridman, Curr. Top. Microbiol. Immunol., 244:13-27 1999.
Max et al., Cell 29:691-699 1982.
McKnight, S. L., Scientific American 54-64, 1991.
Metcalfe et al., Physiol. Rev., 77:1033-1079 1997.
O'Shea, E. K. et al., Science 243: 38-542 1989.
Ott and Cambier, J. Allergy Clin. Immunol., 106(3):429-440 2000.
Peat and Li, J. Allergy Clin. Immunol., 103:1-10 1999.
Peng et al., J. Immunol., 148:129-136 1992.
Phillips and Parker, J. Immunol., 132:627-632 1984.
Presta et al., J. Biol. Chem., 269:26368-26373 1994.
Rattan et al., Ann. N.Y Acad. Sci. 663:48-62 1992.
Roitt et al., Immunology, Fifth Edition, , eds., pp. 302-317, 1998.
Saxon et al., Current Opinion in Allergy & Clinical Immunology 4, 563-568, 2004.
Saxon et al., J. Immunol., 147:4000 1991.
Schmidt-Dorr. T. et al., Biochemistry 30:9657-9664 1991.
Seifter et al., “Analysis for protein modifications and nonprotein cofactors,” Meth. Enzymol., 182:626-646 1990.
Shields et al., J Biol. Chem., 276, 6591-604 2001.
Sreekrishna et al., J. Basic Microbiol. 28:165-278 1988.
Takahashi et al., Cell 29:671-679 1982.
Tunon de Lara, Rev. Mal. Respir., 13(1):27-36 1996.
Urlaub and Chasin, Proc. Natl. Acad. Sci., 77:4216 1980.
Wang and Hanson, “Parenteral Formulations of Proteins and Peptides: Stability and Stablizers”, Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42-2S, (1998).
Watson et al., Vet. Immunol. Immunopathol. 73:323-9 2000.
Wells et al., Gene 34:315 1985.
Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 1986.
Wetmur et al, J. Mol. Biol. 31:349-70 1966.
Wetmur et al, Critical Reviews in Biochemistry and Molecular Biology, 26(34):227-59 1991.
Wines et al., J. Immunol., 164(10):5313-5318 2000.
Wold, F., “Posttranslational Protein Modifications: Perspectives and Prospects,” in Posttranslational Covalent Modification of Proteins, Johnson, B. C., ed., Academic Press, New York, pp. 1-12, 1981.
Yodoi et al., Ciba Found. Symp., 147:133-148 1989.
Zhang K. et al., J. Allergy Clin. Imm., 114, pp. 321-327 2004.
Zhang et al., J. Exp. Med. 176:233-243 1992.
Zhu D. et al., Nat Med 8, 518-21 2002.
Zoller & Smith, DNA 3:479-488 1984.
Zoller et al., Methods Enzymol., 100:468-500 1983.
Zoller et al., Nucl. Acids Res., 10:6487 1987.
Saxon Andrew
Zhang Ke
Zhu Daocheng
Dreger Ginger R.
Fox James A.
Goodwin & Procter LLP
Szperka Michael
The Regents of the University of California
LandOfFree
Modified fusion molecules for treatment of allergic disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified fusion molecules for treatment of allergic disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified fusion molecules for treatment of allergic disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4081156